Literature DB >> 32786131

Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection.

P Cuhna1, B Herlin1, K Vassilev1, A Kas2,3,4, S Lehericy3,4,5, Y Worbe3,6, E Apartis3,4,6, M Vidailhet3,4,7, S Dupont1,3,4,8.   

Abstract

Entities:  

Keywords:  SARS-CoV-2 infection; movement disorders; neurological complications

Mesh:

Year:  2020        PMID: 32786131      PMCID: PMC7436483          DOI: 10.1111/ene.14474

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.288


× No keyword cloud information.
New forms of neurological complications of severe SARS‐CoV‐2 infection have been described, mainly including encephalopathy, agitation and confusion [1]. Only one publication reveals the emergence of de novo myoclonus in three patients [2], with most publications reporting the aggravation of pre‐existing abnormal movements disorders. Here, we identified and characterized in depth clinically a new type of delayed onset movement disorder in five patients who were admitted to the Assistance Publique – Hôpitaux de Paris intensive care unit (ICU) for severe SARS‐CoV‐2 infection. All patients underwent intubation and mechanical ventilation. Abnormal movements developed 23 ± 7 days (mean ± SD) after ICU discharge. Upper limb postural and action tremor was observed in four patients; one of them (patient 2) also had irregular orthostatic tremor and one patient (patient 4) had bilateral upper limb jerky/myoclonic abnormal movements at rest and during posture and action (Table 1). Associated signs included a moderate proximal motor deficit attributed to a critical illness myopathy in four patients and a mild hemiparesis attributed to a critical illness neuropathy confirmed by electroneuromyography in one patient.
Table 1

Clinical and radiological characteristics of five patients presenting with new onset movement disorder

VariablePatient 1Patient 2Patient 3Patient 4Patient 5
Age, years5167346648
SexMaleMaleMaleFemaleMale
Medical historyDisc herniationHypertension, poliomyelitisHepatitis B healed, typhoidHypertension, nephroangio‐sclerosis with severe renal insufficiency stage V, hepatitis B healedHypertension, obesity
Nasopharyngeal swabs for SARS‐CoV‐2 RNAPositivePositivePositivePositivePositive
Delay between the onset of symptoms and the diagnosis of SARS‐CoV‐2, days985117
ICU
Prone positioningYesYesYesYes
Extracorporeal membrane oxygenation procedure (ECMO), days14918
Tracheotomy, weeks3
Average length of stay in ICU, days1223251934
Time to neurological presentation after extubation, days1731142924
Average weight loss, kg5615616
Other complications of SARS‐CoV‐2 infectionPneumopathyPneumopathyPneumopathyPneumopathy, worsening renal failure requiring dialysis, delirium after extubation requiring haloperidol medication that was rapidly discontinuedPneumopathy
Neurological examination in rehabilitation unit
Type of tremorAction tremor predominant on the right hemibodyPostural and action tremor of upper and lower limbs + orthostatic tremorPostural and action tremor of the upper limbsJerky tremor of the upper limbsPostural and action tremor of the upper limb
MyoclonusNoCortical and subcorticalNoCortical and subcorticalNo
Pyramidal syndromeNoNoNoNoNo
Extrapyramidal syndromeNoNoNoNoNo
Motor deficitMild global proximal deficit predominating on the right sideMild right hemiparesisMild global proximal deficitMild global proximal deficitMild proximal belt deficit
Critical illness neuropathyYesNoNoNoNo
Critical illness myopathyYesNoYesYesYes
Abnormal movement recordingCombination of cortical and subcortical myoclonusCombination of cortical and subcortical myoclonus
MRI
Standard MRIBilateral frontotemporal hypoperfusionCorpus callosum microbleedsCorpus callosum microbleedsDeep and peripheral microbleedsCorpus callosum microbleeds
Neuromelanin sequenceLoss of visibility of the nigrosomesNormalNormalNormalNormal
DaTScanNormalNormalNormalNormal

DaTScan, 123I[A1] ‐FP‐CIT SPECT; ICU, intensive care unit; MRI, magnetic resonance imaging.

Clinical and radiological characteristics of five patients presenting with new onset movement disorder DaTScan, 123I[A1] ‐FP‐CIT SPECT; ICU, intensive care unit; MRI, magnetic resonance imaging. Electrophysiological exploration of the movement disorders was performed in patients 2 and 4 and recorded myoclonic jerks of short duration (40–60 ms) that were synchronous among the electromyography (EMG) traces, associated with post‐myoclonic inhibition period in one patient and with jerks of longer duration (50–100 ms) and increased long loop C‐reflex with latency of 50 ms recorded from thenar muscles in the second. Overall, the recordings supported a mixed cortical–subcortical pattern of myoclonic jerks (Fig. 1).
Figure 1

Myoclonus electrophysiology (patients 2 and 4). REW, radial extensor of wrist; RFW, radial flexor of wrist; 1st MI, first interossal muscle; Acc, accelorometer; Trap, trapezius muscle. (a) Surface EMG of right superior member, patient 2: REW, myoclonic bursts of 40–44 ms with 36–44 ms of post‐myoclonic inhibition period (indicated with *); RFW, myoclonic bursts of 24 ms with 66 ms of post‐myoclonic inhibition period (indicated with *); 1st MI, myoclonic bursts of 36 ms with 86 ms of post‐myoclonic inhibition period (indicated with *). (b) Surface EMG of right superior member, patient 4: irregular myoclonic activity on the EMG of trapezius and REW with 70–94 ms of duration of myoclonic bursts. (c) Long loop C reflex with latency of 50 ms recorded from the thenar muscles of patient 4.

Myoclonus electrophysiology (patients 2 and 4). REW, radial extensor of wrist; RFW, radial flexor of wrist; 1st MI, first interossal muscle; Acc, accelorometer; Trap, trapezius muscle. (a) Surface EMG of right superior member, patient 2: REW, myoclonic bursts of 40–44 ms with 36–44 ms of post‐myoclonic inhibition period (indicated with *); RFW, myoclonic bursts of 24 ms with 66 ms of post‐myoclonic inhibition period (indicated with *); 1st MI, myoclonic bursts of 36 ms with 86 ms of post‐myoclonic inhibition period (indicated with *). (b) Surface EMG of right superior member, patient 4: irregular myoclonic activity on the EMG of trapezius and REW with 70–94 ms of duration of myoclonic bursts. (c) Long loop C reflex with latency of 50 ms recorded from the thenar muscles of patient 4. Magnetic resonance imaging (MRI) (3 T) performed in all patients showed in four patients microbleeds which are non‐specific injuries associated with the resuscitation setting [3] and a bilateral frontotemporal hypoperfusion in one patient. Neuromelanin‐sensitive MRI showed that the dorsal nigral hyperintensity sign was bilaterally present in four patients but was asymmetrical and only present in one hemisphere in patient 1. Single photon emission computed tomography (SPECT) with 123I‐FP‐CIT (DaTScan) performed in four patients showed no significant decrease of striatal uptake in any of them. Several pathophysiological mechanisms may be hypothesized here: (i) direct central nervous system damage by SARS‐CoV‐2 or of post infectious/immune‐mediated origin, (ii) metabolic (renal failure) and post‐hypoxic myoclonus [4, 5] no hypothesis is exclusive of the others. For the first hypothesis, SARS‐CoV‐2 is known to enter the brain [5], where it can bind to the enzyme angiotensin‐converting enzyme 2 and cause neuronal death. In line with that, we observed MRI abnormalities such as alterations of nigrosomes (substantia nigra) and frontotemporal hypoperfusion on MRI perfusion sequence that could be directly or indirectly related to SARS‐CoV‐2 [4]. The delayed onset (3 weeks after ICU discharge) of these movement disorders can also be in favor of SARS‐COV‐2 related immune implication. Alternatively, cortical and subcortical myoclonus may be related to post‐infectious myoclonus, although this hypothesis is less likely in the absence of opsoclonus or ataxia. Finally, electrophysiological exploration documented cortical (abnormal long loop C‐reflex) and subcortical (long duration bursts) myoclonus. We thus cannot exclude a combination of chronic post‐hypoxic myoclonus with action and intention myoclonus of subcortical and cortical origin with possible additional metabolic origin in patient 4 with renal failure syndrome.

Disclosure of conflicts of interest

The authors declare no financial or other conflicts of interest.
  5 in total

Review 1.  Myoclonus in the critically ill: Diagnosis, management, and clinical impact.

Authors:  Raoul Sutter; Anette Ristic; Stephan Rüegg; Peter Fuhr
Journal:  Clin Neurophysiol       Date:  2015-08-29       Impact factor: 3.708

2.  Critical Illness-Associated Cerebral Microbleeds.

Authors:  Evgenia M Fanou; Jonathan M Coutinho; Patrick Shannon; Tim-Rasmus Kiehl; Marcel M Levi; M Elizabeth Wilcox; Richard I Aviv; Daniel M Mandell
Journal:  Stroke       Date:  2017-02-24       Impact factor: 7.914

Review 3.  Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment.

Authors:  Harsh V Gupta; John N Caviness
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-09-17

4.  Generalized myoclonus in COVID-19.

Authors:  Pablo Rábano-Suárez; Laura Bermejo-Guerrero; Antonio Méndez-Guerrero; Javier Parra-Serrano; Daniel Toledo-Alfocea; Daniel Sánchez-Tejerina; Teresa Santos-Fernández; María Dolores Folgueira-López; Judit Gutiérrez-Gutiérrez; Blanca Ayuso-García; Jesús González de la Aleja; Julián Benito-León
Journal:  Neurology       Date:  2020-05-21       Impact factor: 9.910

5.  Neurologic Features in Severe SARS-CoV-2 Infection.

Authors:  Julie Helms; Stéphane Kremer; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Christine Kummerlen; Olivier Collange; Clotilde Boulay; Samira Fafi-Kremer; Mickaël Ohana; Mathieu Anheim; Ferhat Meziani
Journal:  N Engl J Med       Date:  2020-04-15       Impact factor: 91.245

  5 in total
  7 in total

Review 1.  Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).

Authors:  Biyan Nathanael Harapan; Hyeon Joo Yoo
Journal:  J Neurol       Date:  2021-01-23       Impact factor: 4.849

2.  Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms.

Authors:  V A Blanco-Palmero; F J Azcárate-Díaz; M Ruiz-Ortiz; M I Laespada-García; P Rábano-Suárez; A Méndez-Guerrero; M Aramendi-Ramos; J L Eguiburu; A Pérez-Rivilla; A Marchán-López; M Rubio-Fernández; E Carro; J González de la Aleja
Journal:  J Neurol       Date:  2021-02-19       Impact factor: 4.849

Review 3.  Clinical and Pathophysiologic Spectrum of Neuro-COVID.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Mol Neurobiol       Date:  2021-04-08       Impact factor: 5.590

4.  [COVID 19 and myoclonus, do hemodialysis patients have more risk?]

Authors:  Salia Virxinia Pol Heres; Nuria Aresté Fosalba; Ana Barragán Prieto; Wenceslao Adrián Aguilera Morales; Mercedes Salgueira Lazo
Journal:  Nefrologia       Date:  2021-12-07       Impact factor: 2.033

Review 5.  New-Onset Movement Disorders Associated with COVID-19.

Authors:  Pedro Renato P Brandão; Talyta C Grippe; Danilo A Pereira; Renato P Munhoz; Francisco Cardoso
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2021-07-08

Review 6.  Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review.

Authors:  Jason L Chan; Keely A Murphy; Justyna R Sarna
Journal:  J Neurol       Date:  2021-02-22       Impact factor: 4.849

7.  COVID-19-associated myoclonus in a series of five critically ill patients.

Authors:  Alexander Grieb; Tamara Seitz; Reinhard Kitzberger; Manfred Schmidbauer; Wolfgang Hoepler; Sebastian Baumgartner; Marianna T Traugott; Erich Pawelka; Mario Karolyi; Georg Strasser; Karolina Knibbe; Hermann Laferl; Alexander Zoufaly; Christoph Wenisch; Stephanie Neuhold
Journal:  Wien Klin Wochenschr       Date:  2021-06-15       Impact factor: 1.704

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.